Previous Article | Next Article ![]()
Infect Immun, February 1998, p. 827-829, Vol. 66, No. 2
Department of Pathology, College of
Veterinary Medicine and Biomedical Sciences, Colorado State
University, Fort Collins, Colorado 80523-1671
Received 5 June 1997/Returned for modification 18 July
1997/Accepted 21 November 1997
Leishmania major and Leishmania
braziliensis both cause cutaneous leishmaniasis, but the former
kills BALB/c mice while the latter is killed by the mice. This
killing of L. braziliensis occurred by a gamma
interferon-dependent mechanism, potentially made possible by the
observed lack of high interleukin-4 production.
The most widely studied model for
cutaneous leishmaniasis is infection of mice with Leishmania
major, wherein it has been observed that certain mice (e.g., C3H)
develop a parasite-specific Th1 response (high levels of gamma
interferon [IFN- The course of cutaneous lesion development following infection with
L. major or L. braziliensis in BALB/c
mice.
BALB/cBy mice (National Cancer Institute, Frederick, Md.)
were injected with either 106 L. major
(R/SU/59/Neal P) (22) or 107 L. braziliensis (MAN/BR/LTB-111) (10) organisms in a hind
footpad. Because L. braziliensis is weakly infectious
for mice, a dose of 107 parasites was required to obtain
consistent results in the assay systems used. On the other hand,
because L. major is quite infectious for BALB/c mice, a
lower dose of L. major (106 organisms) was
used; a dose of 107 L. major organisms
would have overwhelmed the mice so rapidly that there would not have
been sufficient time to compare the courses of infection with the two
species of parasites. Using this approach, we found that the majority
of both species were killed within the first 3 days of infection. At
this time the numbers of parasites remaining in the developing footpad
lesions were similar for the two species (parasites were enumerated by limiting-dilution analysis; for techniques, see reference
11): 1.4 × 104 L. major organisms (95% confidence limits, 0.2 × 104 to 2.6 × 104) and 5.6 × 104 L. braziliensis organisms (confidence
limits, 0.4 × 104 to 10.7 × 104).
Such massive destruction of L. major within the first few
days of infection has been reported before (22). Beyond
day 3 postinfection, L. major replicated to achieve a
712-fold expansion by day 42 postinfection. In contrast, L. braziliensis doubled its numbers by day 7 postinfection and
thereafter was gradually destroyed, so that beyond day 42 postinfection
the parasite could not be detected. Cutaneous lesion development
directly correlated with lesion (footpad) parasite burden.
L. major induced a rapid increase in footpad size, such
that by day 42 postinfection, footpad thickness had tripled and lesions
had become ulcerated and necrotic (at which point the animals were
sacrificed). L. braziliensis induced modest (never more
than a 50% increase in footpad thickness) lesions that were nodular
and never ulcerated.
Production of Th1- and Th2-associated cytokines by BALB/c mice
infected with L. major or L. braziliensis.
Cytokines play counteracting roles in the control
(e.g., IFN-
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Analysis of the Immune Responses of Mice to
Infection with Leishmania braziliensis
and
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
] and low levels of interleukin-4 [IL-4]), which
often is associated with cure, while other mice (BALB/c) develop a Th2
response (low levels of IFN-
and high levels of IL-4), which leads
to disease progression (reviewed in references 4, 8, 13,
14, and 21). In contrast, although
Leishmania braziliensis induces a disease that is a serious
health problem in South America, relatively little experimental work
has been done to characterize the immune response to this parasite,
probably because the parasite is weakly infectious for mice (6,
12). To examine why L. braziliensis is weakly infectious, we infected the same mouse strain (BALB/c) with either L. major (which kills BALB/c mice) or L. braziliensis (which BALB/c mice kill) and compared the development
of cutaneous lesions and the immune responses to the two species of
parasites.
) or exacerbation (e.g., IL-4) of L. major infection. Therefore, we determined the cytokines produced
by lymph node cells taken from BALB/c mice infected with either
L. major or L. braziliensis. Three to
five mice from each group were killed for evaluation at various
times postinfection. Single-cell suspensions were prepared from
the lymph nodes draining the lesion, and the cells were placed into culture as described elsewhere (20). To assess IL-4,
IL-10, and IFN-
production, culture supernatants were harvested
72 h later (a time when peak production of the cytokines
was achieved) and analyzed for the presence of the cytokines
by using enzyme-linked immunosorbent assays (ELISA) described
elsewhere (5, 20). For tumor necrosis factor alpha
(TNF-
) production, culture supernatants were harvested 6, 24, 48, and 72 h later and analyzed for TNF by ELISA (capture and
detection antibodies and recombinant TNF standard were obtained from
PharMingen [San Diego, Calif.]).
plays a protective role in leishmaniasis and because
BALB/c mice cure an infection with L. braziliensis, we anticipated that these mice would produce more IFN-
than BALB/c mice
infected with L. major. BALB/c mice were infected with
L. braziliensis or L. major, and at
varying times after infection (day 3, 7, 21, or 42), the lymph node
cells draining the lesion were assessed for IFN-
production. The
levels of IFN-
produced were not different. L. braziliensis elicited 27.8 ± 13.5 ng of IFN-
/ml of
culture supernatant, while L. major elicited 17.7 ± 7.3 (the numbers were obtained by averaging the amounts of IFN-
produced at the four time points ± standard deviation [SD]).
Using the same approach, we also found that C3H mice infected with
L. braziliensis produced an average of 47.9 ± 32.2 ng of IFN-
/ml of culture supernatant. Analysis of IL-10
production yielded results similar to those for IFN-
; L. braziliensis elicited 2.1 ± 1.5 ng of IL-10/ml of culture
supernatant, and L. major elicited 2.9 ± 1.8 ng/ml. Finally, TNF-
production in response to infection with either
species of parasite was not detected. This inability to detect TNF-
production was not due to technical failure, since C3H mice produced
substantial levels of TNF-
following infection with L. braziliensis (e.g., 257.7 pg/ml of culture supernatant at day 3 postinfection).
|
The course of cutaneous lesion development following infection with
L. braziliensis in BALB/c mice treated with either
anti-IFN-
or anti-IL-4 antibody.
Because IL-4 can inhibit the
protective effects of IFN-
in mice infected with L. major (7, 9), and because L. braziliensis-infected BALB/c mice produced significantly less IL-4
than L. major-infected BALB/c mice (Table 1), we
hypothesized that the amount of IFN-
produced by L. braziliensis-infected mice might be sufficient to control
infection. Therefore, we treated L. braziliensis-infected mice with a neutralizing anti-IFN-
.
preparation (anti-IFN-
was purified from the ascites fluid of the anti-IFN-
-producing hybridoma XMG1.2 [a gift from R. Coffman, DNAX, Palo Alto, Calif.] by salt precipitation
[17, 18;]) by determining whether it would prevent
C3H/HeJ mice (National Cancer Institute) from healing an infection with
L. major as reported by others (3). Our
anti-IFN-
preparation converted C3H mice into animals completely
susceptible to infection with L. major (see Fig. 1,
inset). Since C3H mice produce considerably more IFN-
than
BALB/c mice following infection with L. major
(16), and since BALB/c mice produce equivalent amounts of
the cytokine following infection with either L. braziliensis or L. major, our preparation of
anti-IFN-
would be more than sufficient to neutralize IFN-
in
BALB/c mice infected with L. braziliensis.
Treating L. braziliensis-infected BALB/c mice
with anti-IFN-
(by intraperitoneal injections of 1.0 mg of
XMG1.2 on the day of infection and at weekly intervals thereafter until
the completion of the experiment) significantly enhanced lesion size
and prevented the mice from resolving their infection (Fig.
1). In addition, anti-IFN-
treatment caused mice to produce more IL-4 in response to infection
with L. braziliensis. For instance, at 2 weeks
following infection, lymph node cells draining the lesion in treated
mice produced 58.5 ± 1.6 pg of IL-4/ml (mean ± SD) when the
cells were restimulated in culture with L. braziliensis. In contrast, untreated control mice produced
10.8 ± 1.6 pg of IL-4/ml, or 5.4-fold less IL-4 (in cultures not
restimulated with L. braziliensis, no IL-4 was
detected). Finally, by day 144 of infection, anti-IFN-
treatment had
markedly enhanced parasite burden in the lesions (122 parasites/lesion in control mice versus 43.5 × 106 in treated mice,
which is a 356,557-fold difference), which resulted in systemic
infection with L. braziliensis, as evidenced by the fact that large numbers of the parasite (3.58 × 104)
could be detected in the opposing (uninfected) footpad (Fig. 1). It is
possible that parasites could be isolated from the opposing footpad
because the L. braziliensis strain used (LTB-111) was originally isolated from a cutaneous lesion. Therefore, the parasite may prefer the lower temperature of cutaneous sites. Taken together, these data suggest that an IFN-
-dependent mechanism is responsible for the killing of L. braziliensis by BALB/c mice.
|
(TGF-
) also inhibits Th1
responses. TGF-
correlates with susceptibility to infection with
both L. braziliensis (2; reviewed in
reference 13) and L. major
(19). However, we have been unable to detect TGF-
(protein or mRNA, in vitro or in vivo) following infection with
L. braziliensis. Since different isolates of
L. braziliensis vary in their ability to induce TGF-
production (1), it is possible that LTB-111 is a poor
inducer of TGF-
.
In conclusion, the data presented here extend the Th1 (protective)/Th2
(exacerbative) paradigm in leishmaniasis established by injection of
different mouse strains with L. major. However, the
approach taken here is unique. The Th1/Th2 paradigm with L. major was formulated by injecting different mouse strains with the
parasite or by injecting the same mouse strain with the parasite followed by intervention with neutralizing anti-cytokines (anti-IL-4 or
anti-IFN-
) (reviewed in references 4, 8, 13, 14, and 21). Here, the same mouse strain (BALB/c) was
injected with two leishmanial species that cause cutaneous disease;
parasites that elicited a strong Th2 (IL-4) response survived
(L. major), while those that did not (L. braziliensis) were killed.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by NIH grant AI-29955. H.C.L. received partial support from a World Health Organization TDR-WHO scholarship (M8/181/4/L.238).
The technical assistance of Monica Estay and Julie Bleyenberg is gratefully acknowledged.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1671. Phone: (970) 491-4964. Fax: (970) 491-0603. E-mail: rtitus{at}vines.colostate.edu.
Present address: Departamento de Parasitologia, Microbiologia e
Imunologia, Faculdade de Medicina de Ribeirao Preto, Universidade de
Sao Paulo
Campus de Ribeirao Preto, Ribeirao Preto SP
14.049- 900, Brazil.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Barral, A.,
M. Barral-Netto,
E. C. Yong,
C. E. Brownell,
D. R. Twardzik, and S. G. Reed.
1993.
Transforming growth factor as a virulence mechanism for Leishmania braziliensis.
Proc. Natl. Acad. Sci. USA
90:3442-3446 |
| 2. |
Barral-Netto, M.,
A. Barral,
C. E. Brownell,
Y. A. W. Skeiky,
L. R. Ellingsworth,
D. R. Twardzik, and S. G. Reed.
1992.
Transforming growth factor- in leishmanial infection: a parasite escape mechanism.
Science
257:545-548 |
| 3. |
Belosevic, M.,
D. S. Finbloom,
P. van der Meide,
M. V. Slayter, and C. A. Nacy.
1989.
Administration of monoclonal anti-IFN- antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
J. Immunol.
143:266-274[Abstract].
|
| 4. | Bogdan, C., A. Gessner, and M. Rollinghoff. 1993. Cytokines in leishmaniasis: a complex network of stimulatory and inhibitory interactions. Immunobiology 189:356-396[Medline]. |
| 5. | Chakkalath, H. R., and R. G. Titus. 1994. Leishmania major-parasitized macrophages augment Th2-type T cell activation. J. Immunol. 153:4378-4387[Abstract]. |
| 6. | Childs, G. E., L. K. Lighther, L. A. McKinney, M. Groves, E. Price, and L. Hendricks. 1984. Inbred mice as model hosts for cutaneous leishmaniasis. I. Resistance and susceptibility to infection with Leishmania braziliensis, L. mexicana and L. aethiopica. Ann. Trop. Med. Parasitol. 78:25-34[Medline]. |
| 7. |
Lehn, M.,
W. Y. Weiser,
S. Engelhorn,
S. Gillis, and H. G. Remold.
1989.
IL-4 inhibits H2O2 production and antileishmanial capacity of human cultured monocytes mediated by IFN- .
J. Immunol.
143:3020-3024[Abstract].
|
| 8. | Liew, F. Y., and C. A. O'Donnell. 1993. Immunology of leishmaniasis. Adv. Parasitol. 32:161-259[Medline]. |
| 9. |
Liew, F. Y.,
S. Millott,
Y. Li,
R. Lelchuk,
W. L. Chan, and H. Ziltener.
1989.
Macrophage activation by interferon- from host-protective T cells is inhibited by interleukin (IL) 3 and IL-4 produced by disease-promoting T cells in leishmaniasis.
Eur. J. Immunol.
19:1227-1232[Medline].
|
| 10. | Lima, H. C., and R. G. Titus. 1996. Effects of sand fly vector saliva on development of cutaneous lesions and the immune response to Leishmania braziliensis in BALB/c mice. Infect. Immun. 64:5442-5445[Abstract]. |
| 11. | Lima, H. C., J. A. Bleyenberg, and R. G. Titus. 1997. A simple method for quantifying Leishmania in tissues of infected animals. Parasitol. Today 13:80-82. [Medline] |
| 12. | Neal, R. A., and C. Hale. 1983. A comparative study of susceptibility of inbred and outbred mouse strains compared with hamsters to infection with New World cutaneous leishmaniases. Parasitology 87:7-13. |
| 13. | Reed, S. G., and P. Scott. 1993. T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. 5:524-531[Medline]. |
| 14. | Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-177[Medline]. |
| 15. |
Sadick, M. D.,
F. P. Heinzel,
B. J. Holaday,
R. T. Pu,
R. S. Dawkins, and R. M. Locksley.
1990.
Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon -independent mechanism.
J. Exp. Med.
171:115-127 |
| 16. | Scharton-Kersten, T., and P. Scott. 1995. The role of the innate immune response in Th1 cell development following Leishmania major infection. J. Leukocyte Biol. 57:515-522[Abstract]. |
| 17. |
Shankar, A., and R. G. Titus.
1993.
Leishmania major-specific, CD4+, MHC class-II-restricted T cells derived in vitro from lymphoid tissues of naive mice.
J. Exp. Med.
178:101-111 |
| 18. |
Shankar, A. H., and R. G. Titus.
1997.
The influence of antigen presenting cell type and IFN- on priming and cytokine secretion of Leishmania major-specific T cells.
J. Infect. Dis.
175:151-157[Medline].
|
| 19. |
Stenger, S.,
H. Thuring,
M. Rollinghoff, and C. Bogdan.
1994.
Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major.
J. Exp. Med.
180:783-793 |
| 20. | Theodos, C. M., A. Shankar, A. L. Glasebrook, W. D. Roeder, and R. G. Titus. 1994. The effect of treating with anti-interleukin-1 receptor antibody on the course of experimental murine cutaneous leishmaniasis. Parasite Immunol. 16:571-577[Medline]. |
| 21. | Titus, R. G., C. M. Theodos, A. Shankar, and L. R. Hall. 1994. Interactions between Leishmania major and macrophages. Immunol. Ser. 60:437-459[Medline]. |
| 22. | Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545-555[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»